



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

August 2019





HIV/AIDS Drug Treatment Program

Monthly Report

© 2019 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
608 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8202
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.cfenet.ubc.ca
Email: info@cfenet.ubc.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)



BRITISH COLUMBIA
CENTRE for EXCELLENCE
in HIV/AIDS



This document is best viewed in colour.
Drug definitions available in the back.



EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

August 2019

N = 7379



Health Authority	Male	Female	All
FRASER	1435	432	1867
INTERIOR	414	97	511
NORTHERN	130	85	215
VANCOUVER COASTAL	3381	448	3829
VANCOUVER ISLAND	763	155	918
	6123	1217	7340
		Unknown/not stated:	39
		Total:	7379

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (August 2014 - August 2019)






1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (August 2014 - August 2019)






1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (August 2014 - August 2019)






1.5 BC-CfE Enrollment: New Antiretroviral Participants (August 2014 - August 2019)






1.6 Percent Distribution of Active Participants by CD4 Count (August 2014 - August 2019)






1.7 Percent Distribution of Inactive Participants by CD4 Count (August 2014 - August 2019)





1.8 Active and Inactive Participants (August 2014 - August 2019)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (August 2014 - August 2019)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (August 2014 - August 2019)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(August 2014 - August 2019)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT
(August 2014 - August 2019)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(August 2014 - August 2019)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (August 2014 - August 2019)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(August 2014 - August 2019)





1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT
(August 2014 - August 2019)




Bictegravir not currently available on BC-CfE Formulary. Drug supplied by the manufacturer for study rollover purposes





1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(August 2014 - August 2019)




Bictegravir not currently available on BC-CfE Formulary. Drug supplied by the manufacturer for study rollover purposes






1.18 Baseline CD4 for Antiretroviral First Starts (August 2014 - August 2019)






**1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
(August 2014 - August 2019)**






1.20 Cumulative Resistance Testing Results by Resistance Category (August 2014 - August 2019)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (August 2014 - August 2019)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2019
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	27	5	0	5	2	615	5	<40	3
1988	28	6	0	6	5	400	6	<40	3
1989	26	51	1	52	40	550	50	<40	3
1990	25	52	1	53	39	500	53	<40	3
1991	25	37	3	40	25	560	39	<40	3
1992	25	62	5	67	44	545	66	<40	3
1993	24	132	15	147	129	560	146	<40	3
1994	23	81	13	94	73	530	91	<40	3
1995	22	132	21	153	116	550	142	<40	3
1996	21	342	56	398	319	580	384	<40	3
1997	19	285	33	318	254	635	295	<40	3
1998	18	199	42	241	190	550	228	<40	3
1999	18	162	40	202	158	550	191	<40	3
2000	18	122	34	156	125	590	146	<40	3
2001	18	121	31	152	115	580	143	<40	3
2002	17	130	23	153	123	540	146	<40	3
2003	16	155	30	185	144	625	179	<40	3
2004	15	159	37	196	158	590	189	<40	3
2005	14	188	43	231	186	650	219	<40	3
2006	13	190	43	233	184	590	223	<40	3
2007	12	260	48	308	248	630	283	<40	3
2008	11	287	67	354	286	650	336	<40	3
2009	10	322	73	395	305	660	369	<40	3
2010	9	281	73	354	292	650	338	<40	3
2011	8	328	75	403	313	700	372	<40	3
2012	7	273	62	335	276	700	319	<40	3
2013	6	271	67	338	267	660	319	<40	3
2014	5	284	55	339	259	700	318	<40	3
2015	4	288	50	338	270	675	320	<40	3
2016	3	286	55	341	256	665	312	<40	3
2017	2	237	35	272	232	625	258	<40	3
2018	1	221	55	276	232	628	271	<40	3
2019	0	185	37	222	193	580	214	<40	3
Total:		6134	1223	7357					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2018	7281	750	2385	<40	2109	610
FEB-2018	7245	762	1904	<40	1743	610
MAR-2018	7270	769	2050	<40	1831	617
APR-2018	7256	776	2080	<40	1841	620
MAY-2018	7274	773	2147	<40	1928	600
JUN-2018	7274	787	2003	<40	1786	610
JUL-2018	7284	785	2037	<40	1810	600
AUG-2018	7289	795	2092	<40	1873	620
SEP-2018	7244	794	2015	<40	1787	620
OCT-2018	7338	775	2170	<40	1945	610
NOV-2018	7341	781	2091	<40	1814	630
DEC-2018	7358	787	1747	<40	1535	620
JAN-2019	7398	792	2456	<40	2141	610
FEB-2019	7380	799	1853	<40	1578	620
MAR-2019	7420	790	2085	<40	1750	610
APR-2019	7378	793	2143	<40	1735	610
MAY-2019	7434	793	2127	<40	1743	620
JUN-2019	7389	803	1929	<40	1549	610
JUL-2019	7397	808	2113	<40	1619	620
AUG-2019	7379	810	2108	<40	1504	610

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2018	1428	3315	79	890	71	380
FEB-2018	1472	3112	79	1036	66	440
MAR-2018	1456	3198	75	59	70	485
APR-2018	1474	3163	73	459	63	497
MAY-2018	1462	3229	93	<40	82	455
JUN-2018	1472	3230	73	1080	70	440
JUL-2018	1472	3261	70	<40	55	570
AUG-2018	1501	3172	64	63	60	485
SEP-2018	1546	2985	88	220	82	410
OCT-2018	1473	3335	79	<50	69	350
NOV-2018	1485	3311	82	87	74	480
DEC-2018	1481	3343	57	355	47	490
JAN-2019	1470	3415	73	73	65	350
FEB-2019	1499	3328	75	108	66	590
MAR-2019	1463	3500	74	885	61	400
APR-2019	1498	3392	79	<50	69	500
MAY-2019	1447	3623	78	87	66	455
JUN-2019	1497	3450	76	<40	65	500
JUL-2019	1487	3513	69	<40	57	530
AUG-2019	1518	3399	80	<50	65	500

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2018	7242	1428	12	12	193	127	56	13218
FEB-2018	7211	1472	11	27	125	169	-31	13255
MAR-2018	7231	1456	17	21	158	138	20	13282
APR-2018	7223	1474	12	15	154	161	-8	13304
MAY-2018	7244	1462	9	12	174	153	21	13329
JUN-2018	7240	1472	13	16	152	156	-4	13351
JUL-2018	7242	1472	13	13	165	155	2	13377
AUG-2018	7253	1501	9	27	158	159	11	13416
SEP-2018	7207	1546	14	15	155	195	-46	13442
OCT-2018	7306	1473	8	19	218	126	99	13478
NOV-2018	7314	1485	5	9	171	164	8	13504
DEC-2018	7330	1481	11	19	152	142	16	13529
JAN-2019	7365	1470	14	20	191	159	35	13564
FEB-2019	7352	1499	7	16	160	179	-13	13593
MAR-2019	7378	1463	15	13	188	147	26	13613
APR-2019	7336	1498	10	16	150	178	-42	13641
MAY-2019	7400	1447	10	21	195	138	64	13683
JUN-2019	7355	1497	14	13	138	180	-45	13704
JUL-2019	7368	1487	13	13	176	161	13	13727
AUG-2019	7357	1518	12	18	164	179	-11	13763

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2018	60	6718	448	55	7281	0.82%	92.27%	6.15%	0.76%	100.00%
FEB-2018	64	6672	450	59	7245	0.88%	92.09%	6.21%	0.81%	100.00%
MAR-2018	62	6699	453	56	7270	0.85%	92.15%	6.23%	0.77%	100.00%
APR-2018	62	6688	449	57	7256	0.85%	92.17%	6.19%	0.79%	100.00%
MAY-2018	69	6692	455	58	7274	0.95%	92.00%	6.26%	0.80%	100.00%
JUN-2018	62	6708	447	57	7274	0.85%	92.22%	6.15%	0.78%	100.00%
JUL-2018	53	6718	458	55	7284	0.73%	92.23%	6.29%	0.76%	100.00%
AUG-2018	56	6723	454	56	7289	0.77%	92.23%	6.23%	0.77%	100.00%
SEP-2018	55	6676	456	57	7244	0.76%	92.16%	6.29%	0.79%	100.00%
OCT-2018	54	6756	474	54	7338	0.74%	92.07%	6.46%	0.74%	100.00%
NOV-2018	53	6763	475	50	7341	0.72%	92.13%	6.47%	0.68%	100.00%
DEC-2018	52	6780	477	49	7358	0.71%	92.14%	6.48%	0.67%	100.00%
JAN-2019	54	6805	486	53	7398	0.73%	91.98%	6.57%	0.72%	100.00%
FEB-2019	52	6787	492	49	7380	0.70%	91.96%	6.67%	0.66%	100.00%
MAR-2019	59	6821	490	50	7420	0.80%	91.93%	6.60%	0.67%	100.00%
APR-2019	56	6784	490	48	7378	0.76%	91.95%	6.64%	0.65%	100.00%
MAY-2019	55	6842	492	45	7434	0.74%	92.04%	6.62%	0.61%	100.00%
JUN-2019	56	6803	482	48	7389	0.76%	92.07%	6.52%	0.65%	100.00%
JUL-2019	59	6798	492	48	7397	0.80%	91.90%	6.65%	0.65%	100.00%
AUG-2019	59	6786	484	50	7379	0.80%	91.96%	6.56%	0.68%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	lamivudine		abacavir		zidovudine		stavudine		didanosine		tenofovir <TAF>		tenofovir <TDF>	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2018	10 36%	3314 47%	9 32%	3070 43%	1 4%	61 1%	0 0%	5 0%	0 0%	4 0%	2 7%	292 4%	16 57%	3628 51%
FEB-2018	13 35%	3315 47%	12 32%	3073 44%	0 0%	61 1%	0 0%	5 0%	0 0%	4 0%	0 0%	299 4%	25 68%	3578 51%
MAR-2018	10 37%	3334 47%	10 37%	3099 44%	0 0%	59 1%	0 0%	4 0%	0 0%	4 0%	0 0%	311 4%	17 63%	3564 50%
APR-2018	5 23%	3342 47%	5 23%	3111 44%	0 0%	55 1%	0 0%	3 0%	0 0%	4 0%	2 9%	333 5%	15 68%	3533 50%
MAY-2018	9 39%	3351 48%	8 35%	3125 44%	1 4%	57 1%	0 0%	5 0%	0 0%	4 0%	1 4%	351 5%	13 57%	3504 50%
JUN-2018	7 35%	3365 48%	7 35%	3142 45%	0 0%	53 1%	0 0%	5 0%	0 0%	3 0%	1 5%	379 5%	12 60%	3473 49%
JUL-2018	7 28%	3394 48%	7 28%	3172 45%	0 0%	51 1%	0 0%	5 0%	0 0%	3 0%	4 16%	398 6%	14 56%	3444 49%
AUG-2018	13 33%	3393 48%	14 36%	3181 45%	0 0%	50 1%	0 0%	4 0%	0 0%	3 0%	2 5%	415 6%	23 59%	3413 48%
SEP-2018	4 15%	3377 48%	3 12%	3162 45%	1 4%	47 1%	0 0%	4 0%	0 0%	2 0%	4 15%	446 6%	18 69%	3364 48%
OCT-2018	11 31%	3418 48%	9 26%	3205 45%	1 3%	49 1%	0 0%	3 0%	0 0%	2 0%	0 0%	479 7%	25 71%	3382 47%
NOV-2018	9 35%	3428 48%	8 31%	3214 45%	0 0%	47 1%	0 0%	4 0%	0 0%	2 0%	1 4%	491 7%	17 65%	3351 47%
DEC-2018	8 32%	3446 48%	8 32%	3233 45%	0 0%	45 1%	0 0%	4 0%	0 0%	1 0%	2 8%	504 7%	15 60%	3348 47%
JAN-2019	8 23%	3471 48%	7 20%	3258 45%	1 3%	45 1%	0 0%	4 0%	0 0%	1 0%	1 3%	519 7%	26 74%	3360 47%
FEB-2019	13 45%	3465 48%	12 41%	3264 45%	0 0%	44 1%	0 0%	1 0%	0 0%	1 0%	3 10%	542 8%	13 45%	3310 46%
MAR-2019	6 30%	3479 48%	6 30%	3282 45%	0 0%	43 1%	0 0%	2 0%	0 0%	0 0%	2 10%	559 8%	12 60%	3311 46%
APR-2019	12 43%	3480 48%	12 43%	3288 46%	0 0%	43 1%	0 0%	2 0%	0 0%	0 0%	2 7%	586 8%	14 50%	3255 45%
MAY-2019	14 34%	3510 49%	14 34%	3318 46%	0 0%	43 1%	0 0%	2 0%	0 0%	1 0%	4 10%	593 8%	23 56%	3266 45%
JUN-2019	3 14%	3493 49%	3 14%	3305 46%	0 0%	43 1%	0 0%	2 0%	0 0%	1 0%	2 10%	610 8%	16 76%	3213 45%
JUL-2019	8 35%	3517 49%	8 35%	3336 46%	0 0%	39 1%	0 0%	2 0%	0 0%	1 0%	1 4%	626 9%	14 61%	3193 44%
AUG-2019	14 39%	3519 49%	12 33%	3344 47%	2 6%	41 1%	0 0%	1 0%	0 0%	1 0%	2 6%	633 9%	20 56%	3153 44%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





Monthly Report

2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (continued)

	emtricitabine			
	Initial		All	
JAN-2018	18	64%	3704	52%
FEB-2018	24	65%	3672	52%
MAR-2018	17	63%	3670	52%
APR-2018	17	77%	3655	52%
MAY-2018	14	61%	3650	52%
JUN-2018	13	65%	3650	52%
JUL-2018	18	72%	3647	52%
AUG-2018	25	64%	3646	52%
SEP-2018	22	85%	3624	51%
OCT-2018	24	69%	3683	52%
NOV-2018	17	65%	3667	51%
DEC-2018	17	68%	3669	51%
JAN-2019	27	77%	3699	51%
FEB-2019	16	55%	3679	51%
MAR-2019	14	70%	3707	51%
APR-2019	16	57%	3671	51%
MAY-2019	27	66%	3695	51%
JUN-2019	18	86%	3660	51%
JUL-2019	15	65%	3667	51%
AUG-2019	22	61%	3638	51%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	fosamprenavir		atazanavir		darunavir		lopinavir		nelfinavir		ritonavir		saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2018	0 0%	8 0%	3 30%	1313 45%	7 70%	1414 48%	0 0%	195 7%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
FEB-2018	0 0%	6 0%	0 0%	1255 44%	15 100%	1420 49%	0 0%	189 7%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
MAR-2018	0 0%	7 0%	1 9%	1243 43%	10 91%	1438 50%	0 0%	187 6%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
APR-2018	0 0%	6 0%	0 0%	1220 43%	11 100%	1435 50%	0 0%	180 6%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
MAY-2018	0 0%	7 0%	0 0%	1204 42%	5 100%	1438 51%	0 0%	181 6%	0 0%	2 0%	0 0%	1 0%	0 0%	10 0%
JUN-2018	0 0%	7 0%	1 8%	1185 42%	11 92%	1428 51%	0 0%	175 6%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
JUL-2018	0 0%	7 0%	2 20%	1168 42%	7 70%	1438 52%	1 10%	168 6%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
AUG-2018	0 0%	7 0%	5 31%	1155 42%	11 69%	1422 52%	0 0%	166 6%	0 0%	1 0%	0 0%	1 0%	0 0%	8 0%
SEP-2018	0 0%	7 0%	1 14%	1132 42%	6 86%	1404 52%	0 0%	159 6%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
OCT-2018	0 0%	7 0%	3 17%	1121 41%	15 83%	1445 53%	0 0%	153 6%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
NOV-2018	0 0%	6 0%	1 14%	1116 41%	6 86%	1456 53%	0 0%	146 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
DEC-2018	0 0%	5 0%	1 11%	1106 41%	7 78%	1457 54%	1 11%	145 5%	0 0%	0 0%	0 0%	2 0%	0 0%	9 0%
JAN-2019	0 0%	6 0%	1 8%	1098 40%	11 92%	1478 54%	0 0%	140 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
FEB-2019	0 0%	5 0%	2 18%	1071 40%	9 82%	1475 55%	0 0%	138 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
MAR-2019	0 0%	5 0%	2 40%	1054 39%	3 60%	1487 55%	0 0%	133 5%	0 0%	1 0%	0 0%	1 0%	0 0%	7 0%
APR-2019	0 0%	5 0%	1 10%	1030 39%	7 70%	1479 56%	2 20%	133 5%	0 0%	2 0%	0 0%	1 0%	0 0%	7 0%
MAY-2019	0 0%	5 0%	1 8%	1034 39%	11 92%	1481 56%	0 0%	130 5%	0 0%	2 0%	0 0%	1 0%	0 0%	6 0%
JUN-2019	0 0%	5 0%	0 0%	1006 39%	9 100%	1470 57%	0 0%	120 5%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
JUL-2019	0 0%	5 0%	0 0%	986 38%	7 100%	1487 57%	0 0%	113 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
AUG-2019	0 0%	5 0%	0 0%	971 38%	11 92%	1462 57%	1 8%	112 4%	0 0%	1 0%	0 0%	1 0%	0 0%	5 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





Monthly Report

2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	tipranavir			
	Initial		All	
JAN-2018	0	0%	1	0%
FEB-2018	0	0%	1	0%
MAR-2018	0	0%	1	0%
APR-2018	0	0%	1	0%
MAY-2018	0	0%	1	0%
JUN-2018	0	0%	1	0%
JUL-2018	0	0%	1	0%
AUG-2018	0	0%	1	0%
SEP-2018	0	0%	1	0%
OCT-2018	0	0%	1	0%
NOV-2018	0	0%	1	0%
DEC-2018	0	0%	1	0%
JAN-2019	0	0%	1	0%
FEB-2019	0	0%	1	0%
MAR-2019	0	0%	1	0%
APR-2019	0	0%	1	0%
MAY-2019	0	0%	1	0%
JUN-2019	0	0%	1	0%
JUL-2019	0	0%	1	0%
AUG-2019	0	0%	1	0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	doravirine		efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2018	0 0%	0 0%	3 50%	778 37%	1 17%	262 12%	2 33%	757 36%	0 0%	302 14%
FEB-2018	0 0%	0 0%	3 75%	769 37%	0 0%	257 12%	0 0%	749 36%	1 25%	306 15%
MAR-2018	0 0%	0 0%	1 33%	757 37%	0 0%	250 12%	0 0%	736 36%	2 67%	311 15%
APR-2018	0 0%	0 0%	1 50%	745 37%	0 0%	245 12%	0 0%	731 36%	1 50%	318 16%
MAY-2018	0 0%	0 0%	4 67%	725 36%	1 17%	252 12%	0 0%	727 36%	1 17%	316 16%
JUN-2018	0 0%	0 0%	1 50%	720 36%	0 0%	248 12%	0 0%	724 36%	1 50%	313 16%
JUL-2018	0 0%	0 0%	3 60%	721 36%	0 0%	243 12%	0 0%	717 36%	2 40%	313 16%
AUG-2018	0 0%	0 0%	2 100%	714 36%	0 0%	238 12%	0 0%	716 36%	0 0%	308 16%
SEP-2018	0 0%	0 0%	6 100%	706 36%	0 0%	236 12%	0 0%	712 36%	0 0%	311 16%
OCT-2018	0 0%	0 0%	3 60%	696 36%	0 0%	234 12%	0 0%	710 36%	2 40%	323 16%
NOV-2018	0 0%	0 0%	8 80%	687 35%	0 0%	230 12%	0 0%	700 36%	2 20%	322 17%
DEC-2018	0 0%	0 0%	1 100%	684 36%	0 0%	225 12%	0 0%	696 36%	0 0%	319 17%
JAN-2019	0 0%	0 0%	4 80%	669 35%	0 0%	221 12%	1 20%	695 37%	0 0%	318 17%
FEB-2019	0 0%	0 0%	2 67%	668 35%	1 33%	226 12%	0 0%	683 36%	0 0%	313 17%
MAR-2019	0 0%	0 0%	3 75%	660 35%	0 0%	224 12%	1 25%	681 36%	0 0%	322 17%
APR-2019	0 0%	0 0%	4 100%	646 35%	0 0%	223 12%	0 0%	678 36%	0 0%	320 17%
MAY-2019	0 0%	0 0%	5 100%	648 35%	0 0%	219 12%	0 0%	672 36%	0 0%	322 17%
JUN-2019	0 0%	0 0%	3 75%	635 35%	0 0%	211 12%	0 0%	664 36%	1 25%	320 18%
JUL-2019	0 0%	1 0%	2 100%	635 35%	0 0%	211 12%	0 0%	657 36%	0 0%	323 18%
AUG-2019	0 0%	1 0%	2 100%	626 35%	0 0%	207 11%	0 0%	647 36%	0 0%	327 18%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Doravirine not currently available on BC-CfE Formulary





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	bictegravir		dolutegravir		elvitegravir		maraviroc		raltegravir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2018	0 0%	0 0%	9 47%	2003 60%	8 42%	630 19%	0 0%	46 1%	2 11%	685 21%
FEB-2018	0 0%	0 0%	16 70%	2023 60%	6 26%	640 19%	0 0%	45 1%	1 4%	675 20%
MAR-2018	0 0%	0 0%	14 100%	2058 61%	0 0%	645 19%	0 0%	43 1%	0 0%	674 20%
APR-2018	0 0%	0 0%	8 67%	2102 61%	4 33%	653 19%	0 0%	44 1%	0 0%	681 20%
MAY-2018	0 0%	0 0%	13 65%	2136 61%	4 20%	664 19%	1 5%	42 1%	3 15%	675 19%
JUN-2018	0 0%	0 0%	8 73%	2168 62%	2 18%	672 19%	0 0%	42 1%	1 9%	676 19%
JUL-2018	0 0%	0 0%	7 58%	2202 62%	4 33%	674 19%	0 0%	42 1%	1 8%	675 19%
AUG-2018	0 0%	0 0%	23 79%	2252 62%	5 17%	675 19%	0 0%	42 1%	1 3%	671 19%
SEP-2018	0 0%	9 0%	5 36%	2261 62%	9 64%	689 19%	0 0%	41 1%	0 0%	655 18%
OCT-2018	0 0%	17 0%	13 76%	2318 63%	4 24%	708 19%	0 0%	40 1%	0 0%	658 18%
NOV-2018	0 0%	17 0%	11 100%	2344 63%	0 0%	703 19%	0 0%	38 1%	0 0%	650 17%
DEC-2018	0 0%	17 0%	13 76%	2367 63%	4 24%	719 19%	0 0%	39 1%	0 0%	652 17%
JAN-2019	0 0%	16 0%	15 75%	2430 63%	4 20%	730 19%	0 0%	39 1%	1 5%	651 17%
FEB-2019	0 0%	27 1%	16 73%	2437 63%	5 23%	727 19%	0 0%	40 1%	1 5%	653 17%
MAR-2019	0 0%	27 1%	8 62%	2486 64%	5 38%	747 19%	0 0%	38 1%	0 0%	647 17%
APR-2019	0 0%	27 1%	8 57%	2503 64%	3 21%	739 19%	0 0%	36 1%	3 21%	637 16%
MAY-2019	0 0%	27 1%	19 68%	2566 64%	6 21%	749 19%	0 0%	37 1%	3 11%	636 16%
JUN-2019	0 0%	27 1%	10 77%	2570 65%	3 23%	748 19%	0 0%	37 1%	0 0%	625 16%
JUL-2019	0 0%	27 1%	14 82%	2615 65%	3 18%	759 19%	0 0%	38 1%	0 0%	628 16%
AUG-2019	0 0%	27 1%	24 86%	2650 65%	1 4%	758 19%	0 0%	36 1%	3 11%	627 15%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Bictegravir not currently available on BC-CfE Formulary. Drug supplied by the manufacturer for study rollover purposes





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2018	2004	27.52	1644	22.58	2592	35.60	117	1.61	55	0.76	869	11.94
FEB-2018	1961	27.07	1629	22.48	2610	36.02	116	1.60	59	0.81	870	12.01
MAR-2018	1974	27.15	1615	22.21	2644	36.37	113	1.55	56	0.77	868	11.94
APR-2018	1928	26.57	1596	22.00	2696	37.16	114	1.57	57	0.79	865	11.92
MAY-2018	1918	26.37	1575	21.65	2733	37.57	114	1.57	58	0.80	876	12.04
JUN-2018	1903	26.16	1562	21.47	2785	38.29	113	1.55	57	0.78	854	11.74
JUL-2018	1886	25.89	1565	21.49	2814	38.63	110	1.51	55	0.76	854	11.72
AUG-2018	1860	25.52	1549	21.25	2860	39.24	111	1.52	56	0.77	853	11.70
SEP-2018	1823	25.17	1532	21.15	2878	39.73	109	1.50	57	0.79	845	11.66
OCT-2018	1848	25.18	1529	20.84	2946	40.15	104	1.42	54	0.74	857	11.68
NOV-2018	1842	25.09	1522	20.73	2966	40.40	106	1.44	50	0.68	855	11.65
DEC-2018	1835	24.94	1510	20.52	3005	40.84	104	1.41	49	0.67	855	11.62
JAN-2019	1833	24.78	1481	20.02	3063	41.40	100	1.35	53	0.72	868	11.73
FEB-2019	1805	24.46	1479	20.04	3080	41.73	99	1.34	49	0.66	868	11.76
MAR-2019	1795	24.19	1473	19.85	3133	42.22	99	1.33	50	0.67	870	11.73
APR-2019	1763	23.90	1461	19.80	3148	42.67	101	1.37	48	0.65	857	11.62
MAY-2019	1774	23.86	1449	19.49	3211	43.19	97	1.30	45	0.61	858	11.54
JUN-2019	1749	23.67	1440	19.49	3214	43.50	95	1.29	48	0.65	843	11.41
JUL-2019	1720	23.25	1429	19.32	3251	43.95	92	1.24	48	0.65	857	11.59
AUG-2019	1690	22.90	1403	19.01	3300	44.72	94	1.27	50	0.68	842	11.41

Definitions:

n is number of participants on the specified regimen class in the specified month
 % is ratio of n and total number of participants on ART in the specified month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2018	12	1	1	0	4	4	470
FEB-2018	27	3	2	2	6	13	485
MAR-2018	21	4	1	5	4	6	325
APR-2018	15	0	0	5	3	5	480
MAY-2018	12	1	0	4	3	2	370
JUN-2018	16	3	5	1	1	6	237
JUL-2018	13	4	1	3	4	1	284
AUG-2018	27	2	2	6	4	13	450
SEP-2018	15	2	3	1	3	5	405
OCT-2018	19	0	1	2	5	10	525
NOV-2018	9	2	2	2	0	2	185
DEC-2018	19	2	0	5	5	7	380
JAN-2019	20	3	3	2	4	6	390
FEB-2019	16	1	0	6	4	4	400
MAR-2019	13	1	2	1	5	4	450
APR-2019	16	3	3	1	3	4	368
MAY-2019	21	1	0	6	8	4	440
JUN-2019	13	2	1	1	2	5	430
JUL-2019	13	1	1	1	3	7	530
AUG-2019	18	0	1	6	4	6	390

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2018	11956	3652
FEB-2018	11986	3667
MAR-2018	12013	3696
APR-2018	12045	3726
MAY-2018	12080	3751
JUN-2018	12092	3754
JUL-2018	12118	3778
AUG-2018	12132	3773
SEP-2018	12155	3794
OCT-2018	12174	3794
NOV-2018	12211	3813
DEC-2018	12215	3808
JAN-2019	12255	3833
FEB-2019	12263	3832
MAR-2019	12293	3862
APR-2019	12320	3886
MAY-2019	12337	3887
JUN-2019	12337	3892
JUL-2019	12358	3911
AUG-2019	12400	3938

Definitions:

Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved

Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
August 2019

N = 7379

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY







3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participants

August 2019

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



KELOWNA BY POSTAL CODE







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

August 2019

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

August 2019

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

August 2019

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

August 2019

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





**4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
INTERIOR Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	6	6	*
	35-49	11	13	*
	50+	26	37	*
	Total HSDA:	43	56	26
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	73	97	54	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	368	495	288	
THOMPSON/CARIBOO/ SHUSWAP	0-19	*	*	0
	20-34	*	*	12
	35-49	*	*	47
	50+	*	*	84
Total HSDA:	192	257	143	
Total HA:		676	905	511

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	5	5	*
	20-34	61	62	*
	35-49	181	202	*
	50+	429	636	*
Total HA:		676	905	511

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	540	726	414
Female	136	179	97

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	511	54	600	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	18	10
	5 years or more	11	6
	<5 years	14	10
	Total HSDA:	43	26
KOOTENAY BOUNDARY	10 years or more	44	32
	5 years or more	16	11
	<5 years	13	11
	Total HSDA:	73	54
OKANAGAN	10 years or more	227	170
	5 years or more	66	54
	<5 years	75	64
	Total HSDA:	368	288
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	108	74
	5 years or more	39	33
	<5 years	45	36
	Total HSDA:	192	143
Total HA:		676	511

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	397	286
	5 years or more	132	104
	<5 years	147	121
Total HA:		676	511

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	41	59	12	25
KOOTENAY BOUNDARY	69	121	19	43
OKANAGAN	213	918	54	285
THOMPSON/CARIBOO/SHUSWAP	133	505	39	134
Total:	456	1603	124	487

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
Total:	97

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	8	8	8
	20-34	29	31	20
	35-49	107	117	84
	50+	230	304	182
	Total HSDA:		374	460
FRASER NORTH	0-19	10	10	*
	20-34	106	107	*
	35-49	349	381	*
	50+	541	863	*
	Total HSDA:		1006	1361
FRASER SOUTH	0-19	8	8	5
	20-34	122	124	89
	35-49	332	378	279
	50+	533	785	441
	Total HSDA:		995	1295
Total HA:		2375	3116	1867

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	26	26	15
	20-34	257	262	179
	35-49	788	876	625
	50+	1304	1952	1048
Total HA:		2375	3116	1867

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1802	2387	1435
Female	573	729	432

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1867	51	626	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	214	167
	5 years or more	77	61
	<5 years	83	66
	Total HSDA:	374	294
FRASER NORTH	10 years or more	554	394
	5 years or more	248	194
	<5 years	204	171
	Total HSDA:	1006	759
FRASER SOUTH	10 years or more	543	438
	5 years or more	222	176
	<5 years	230	200
	Total HSDA:	995	814
Total HA:		2375	1867

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1311	999
	5 years or more	547	431
	<5 years	517	437
Total HA:		2375	1867

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries FRASER Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	140	491	31	63
FRASER NORTH	248	1557	45	232
FRASER SOUTH	212	1450	44	449
Total:	600	3498	120	744

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	201
FRASER NORTH	636
FRASER SOUTH	503
Total:	1340

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	0
	20-34	*	*	16
	35-49	*	*	60
	50+	*	*	201
	Total HSDA:		331	478
RICHMOND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		176	225
VANCOUVER	0-19	33	33	7
	20-34	438	451	315
	35-49	1389	1569	1005
	50+	2799	4776	2085
	Total HSDA:	4659	6829	3412
Total HA:		5166	7532	3829

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	36	36	8
	20-34	490	504	352
	35-49	1511	1703	1100
	50+	3129	5289	2369
Total HA:		5166	7532	3829

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Unknown	2	2	0
Male	4559	6614	3381
Female	605	916	448

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3829	53	630	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	184	151
	5 years or more	86	73
	<5 years	61	53
	Total HSDA:	331	277
RICHMOND	10 years or more	100	75
	5 years or more	37	31
	<5 years	39	34
	Total HSDA:	176	140
VANCOUVER	10 years or more	2722	1927
	5 years or more	1174	855
	<5 years	763	630
	Total HSDA:	4659	3412
Total HA:		5166	3829

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	3006	2153
5 years or more	1297	959
<5 years	863	717
Total HA:	5166	3829

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	168	490	50	173
RICHMOND	43	287	11	95
VANCOUVER	594	10750	194	5297
Total:	805	11527	255	5565

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	7
RICHMOND	5
VANCOUVER	94
Total:	106

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		320	454
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		125	167
SOUTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		727	1030
Total HA:		1172	1651	918

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	*
	20-34	107	114	*
	35-49	309	360	*
	50+	750	1171	*
Total HA:		1172	1651	918

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	964	1357	763
Female	208	294	155

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	918	54	545	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	173	145
	5 years or more	70	59
	<5 years	77	62
	Total HSDA:	320	266
NORTH VANCOUVER ISLAND	10 years or more	71	56
	5 years or more	31	22
	<5 years	23	20
	Total HSDA:	125	98
SOUTH VANCOUVER ISLAND	10 years or more	418	296
	5 years or more	157	131
	<5 years	152	127
	Total HSDA:	727	554
Total HA:		1172	918

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	662	497
	5 years or more	258	212
	<5 years	252	209
Total HA:		1172	918

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	192	856	72	194
NORTH VANCOUVER ISLAND	136	263	47	79
SOUTH VANCOUVER ISLAND	209	1777	41	555
Total:	537	2896	160	828

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	52
NORTH VANCOUVER ISLAND	38
SOUTH VANCOUVER ISLAND	105
Total:	195

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		41	49
NORTH WEST	0-19	*	*	0
	20-34	*	*	8
	35-49	*	*	14
	50+	*	*	33
	Total HSDA:		68	106
NORTHERN INTERIOR	0-19	5	5	*
	20-34	21	22	*
	35-49	70	89	*
	50+	89	149	*
	Total HSDA:		185	265
Total HA:		294	420	215

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	7	7	*
	20-34	34	36	*
	35-49	107	145	*
	50+	146	232	*
Total HA:		294	420	215

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	178	259	130
Female	116	161	85

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	215	50	540	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	20	*
	5 years or more	13	*
	<5 years	8	*
	Total HSDA:	41	24
NORTH WEST	10 years or more	31	23
	5 years or more	24	22
	<5 years	13	10
	Total HSDA:	68	55
NORTHERN INTERIOR	10 years or more	73	50
	5 years or more	64	52
	<5 years	48	34
	Total HSDA:	185	136
Total HA:		294	215

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	124	84
5 years or more	101	83
<5 years	69	48
Total HA:	294	215

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	39	63	7	8
NORTH WEST	71	161	13	31
NORTHERN INTERIOR	105	461	15	182
Total:	215	685	35	221

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	6
NORTH WEST	20
NORTHERN INTERIOR	15
Total:	41

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	6	10	*
	KOOTENAY BOUNDARY	6	9	*
	OKANAGAN	22	38	*
	THOMPSON/CARIBOO/SHUSWAP	27	46	*
	Total HA:	61	103	42
FRASER	FRASER EAST	44	54	34
	FRASER NORTH	51	87	43
	FRASER SOUTH	72	105	54
	Total HA:	167	246	131
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	26	49	22
	RICHMOND	11	16	9
	VANCOUVER	488	856	377
	Total HA:	525	921	408
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	50	79	44
	NORTH VANCOUVER ISLAND	17	26	14
	SOUTH VANCOUVER ISLAND	36	79	29
	Total HA:	103	184	87
NORTHERN	NORTH EAST	10	12	8
	NORTH WEST	28	57	24
	NORTHERN INTERIOR	68	105	55
	Total HA:	106	174	87
Total:		962	1628	755

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	601	1036	466
Female	361	592	289

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	755	51	480	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir (Ziagen, ABC): a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Amphotericin B (Fungilin): a drug used for treatment of candidiasis and other fungal infections.

Amprenavir (Agenerase, APV): a PROTEASE INHIBITOR from ViiV Healthcare. No longer marketed in Canada.

Antiretroviral (ARV): a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz, ATV): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla (ATP): the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Bictegravir: an INTEGRASE INHIBITOR from Gilead Sciences.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicistat: a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Combivir (CBV): the ViiV Healthcare trade name for a tablet containing both ZIDOVUDINE and LAMIVUDINE.

Complera (CPL): the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista, DRV): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.





Descovy (DSC): the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

Didanosine (Videx, DDI): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay, DTG): an INTEGRASE INHIBITOR from ViiV Healthcare.

Efavirenz (Sustiva, Auro efavirenz, EFV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir (EGV): an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine (FTC): a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon, T20): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intence, ETV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Ethambutol (Myambutol): an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir, fAPV): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya (GNV): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Granulocyte Colony Stimulating Factor (GCSF, Neupogen): a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa (KIV): the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine (3TC): a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra, LPV/r): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.

Maraviroc (Celsentri, MVC): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by





blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Moxifloxacin: a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept, NFV): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune, NVP): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

NRTI: see NUCLEOSIDE ANALOG.

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Octreotide Acetate (Sandostatin): a drug used to treat chronic refractory diarrhea.

Odefsey (ODF): the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Paromomycin (Humatin): an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.





Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix (PZC): the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (RGV, Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant, RPV): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir, RTV): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

Saquinavir (Invirase, SQV): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit, d4T): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild (STR): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus, TPV): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq (TRQ): the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir (TRZ): the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada (TRU): the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.





Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir, AZT): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

